i10X launches Superagent 
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds 
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds 
Anker Innovations announces the listing plan on the Main Board of HKEX with a maximum fundraising of HK$4,631.6 Million* Organ Recovery Systems’ LifePort® Liver Transporter Preserves First Livers for Transplant as Part of the PILOT™ Continued Access Study
When used to preserve donor livers from extended criteria donors, newly reported clinical trial outcomes…
Symmetry Systems Launches Zero Trust for Data
Enables customers to understand where their data is located, who can access it and what…
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
Carrick Therapeutics Closes Series C Financing
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology…
Carrick Therapeutics Closes Series C Financing
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology…
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live…
Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to participate in a live…
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
WALTHAM, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…
Theriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or…
Theriva Biologics to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or…
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Initial CD388 clinical data expected in the first half of 2023 SAN DIEGO, Dec. 01,…
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
Initial CD388 clinical data expected in the first half of 2023 SAN DIEGO, Dec. 01,…
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision…
Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
OPGx-001 is Opus’ first program to enter clinical evaluation and is designed to address vision…
FDA Grants Fast Track Designation to Nuvectis Pharma’s NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
FDA Grants Fast Track Designation to Nuvectis Pharma’s NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis”…
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing…